Study of Enterra Programming With Nocturnal Cycling in Gastroparetics (RESTING)

In order to be eligible to participate in this study, a participant must meet all of the following criteria: Completed informed consent process with signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Male or female, aged ≥18 or ≤70 at time of informed consent; Currently implanted with the Enterra™ Therapy System (Enterra™ II 37800 neurostimulator); High GES output defined as remaining pulse generator expected life of > 9 months from enrollment and less than 4 years from the time of implant; Stable gastroparesis symptoms, in the opinion of the investigator; On stable medical therapy for gastroparesis symptoms; On stable supplemental nutritional support during the month prior to enrollment. A participant who meets any of the following criteria will be excluded from participation in this study: Post-surgical gastroparesis (e.g., fundoplication, Bilroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator; Subjects, in the opinion of the investigator, with profound nausea and/or vomiting at night; Subjects, in the opinion of the investigator, with profound gastroparesis symptoms upon waking in the morning; Subjects without a regular and defined sleep schedule; Pregnancy, or subject that intends to become pregnant during participation in the study; Chemical dependency; Enterra lead impedance measurements ≥ 700 Ohms at screening visit; Life expectancy < 1 year from conditions other than GI diseases; Subjects with an underlying disease leading to follow-up by MRI; Participation in other clinical studies; Subjects involved in current or past medical-related litigation; Subjects with cognitive impairment or other characteristic that would limit subject's ability to complete study requirements.